Aspergillosis is a fungal infection caused by various species of Aspergillus, most notably A. fumigatus. This fungus causes a spectrum of diseases, including allergic bronchopulmonary aspergillosis, aspergilloma, chronic pulmonary aspergillosis, and invasive aspergillosis. The clinical manifestations and severity of aspergillosis can vary depending on individual immune status and the specific species of Aspergillus involved. The recognition of Aspergillus involves pathogen-associated molecular patterns (PAMPs) such as glucan, galactomannan, mannose, and conidial surface proteins. These are recognized by the pathogen recognition receptors present on immune cells such as Toll-like receptors (TLR-1,2,3,4, etc.) and C-type lectins (Dectin-1 and Dectin-2). We discuss the roles of cytokines and pathogen recognition in aspergillosis from both the perspective of human and experimental infection. Several cytokines and chemokines have been implicated in the immune response to Aspergillus infection, including interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), CCR4, CCR17, and other interleukins. For example, allergic bronchopulmonary aspergillosis (ABPA) is characterized by Th2 and Th9 cell-type immunity and involves interleukin (IL)-4, IL-5, IL-13, and IL-10. In contrast, it has been observed that invasive aspergillosis involves Th1 and Th17 cell-type immunity via IFN-γ, IL-1, IL-6, and IL-17. These cytokines activate various immune cells and stimulate the production of other immune molecules, such as antimicrobial peptides and reactive oxygen species, which aid in the clearance of the fungal pathogen. Moreover, they help to initiate and coordinate the immune response, recruit immune cells to the site of infection, and promote clearance of the fungus. Insight into the host response from both human and animal studies may aid in understanding the immune response in aspergillosis, possibly leading to harnessing the power of cytokines or cytokine (receptor) antagonists and transforming them into precise immunotherapeutic strategies. This could advance personalized medicine.

• Aspergillus terreus is an emerging fungal pathogen. • Aspergillus terreus has intrinsic resistance to amphotericin-B. • Fungal infections have emerged During COVID-19 and post COVID-19 era. • CD101, olorofim and PC945 developed as novel antifungal. • Immunocompromised patients are more prone to Aspergillus terreus infection.

Aspergillus species, a group of fungi, can cause various infections, especially in individuals with a weakened immune system. The increasing prevalence of Aspergillus-associated or other fungal infections highlights the urgent need for improved antifungal therapies and preventive strategies, especially as fungal resistance becomes an emerging concern within healthcare settings. New antifungal agents such as ibrexafungerp, olorofim, fosmanogepix, and rezafungin are transforming the treatment of fungal infections by addressing issues of drug resistance, toxicity, and limited efficacy against certain strains. Current antifungal treatments face significant limitations, including the emergence of drug resistance among fungal pathogens, which complicates the treatment of previously manageable infections. Emerging antifungal drugs, such as voriconazole, posaconazole, ravuconazole, SPE-843, and T-2307, are crucial in addressing the growing concern of antifungal resistance and providing alternative treatment. The integration of these innovative antifungal drugs into clinical practice is expected to significantly improve patient management and outcomes in fungal infections. Immunotherapy plays a crucial role in enhancing the immune response against Aspergillus spp. infections, particularly when combined with antifungal agents. The integration of immunotherapy with antifungal treatments, known as combination therapy, is gaining traction as it can help overcome resistance and enhance therapeutic efficacy. Immune modulation during Aspergillus infection is crucial for enhancing host immune responses and developing potential combination therapies. Synergistic mechanisms include blocking PD-1, using cytokines such as IFN-γ and G-CSF, and exploring strategies like NK cell transfer and CAR T-cell therapy to boost immune responses against Aspergillus. Antifungal agents can also modulate the activity of phagocytes, enhancing their antifungal responses through specific receptor interactions. However, challenges remain in translating these findings into clinical practice, necessitating well-designed clinical trials to establish the safety and efficacy of these combined approaches in diverse patient populations.